Thursday 16 October, 2025
Objectives: Despite its complexity, human tumor growth displays a relatively simple time curve. Human tumors were generally found to start…
Read morePoster: Drug/Disease Modelling - Oncology
Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach
Thursday 16 October, 2025
Introduction: Tumor volume doubling time (TVDT), i.e. the time required by a tumor to doubling its volume, is typically used…
Read moreA clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera.
Thursday 16 October, 2025
Introduction: Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by an abnormal production of red and white blood cells…
Read moreA semi-mechanistic pharmacokinetic-pharmacodynamic model of 5-fluorouracil continuous infusion in gastrointestinal cancer patients
Thursday 16 October, 2025
Objectives: The study was aimed to develop a population pharmacokinetic model of 5-fluorouracil continuous infusion and a semi- mechanistic myelosuppression…
Read morePopulation pharmacokinetic model of mitotane enzyme autoinduction in adrenocortical carcinoma patients
Thursday 16 October, 2025
Objectives: Mitotane is the first choice drug for the treatment of adrenocortical carcinoma (ACC). It has a remarkable inter-patient variability, a…
Read morePopulation Pharmacokinetic (PK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Serum M-Protein in an Ongoing Phase 1/2 Study of Modakafusp Alfa in Patients with Relapsed/Refractory Multiple Myeloma
Thursday 16 October, 2025
Introduction: Modakafusp alfa (TAK-573) is a novel, first-in-class Fc-fusion protein designed to deliver attenuated interferon alpha-2b (IFNα2b) to CD38-expressing cells….
Read moreA PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens
Thursday 16 October, 2025
Objectives: PK/PD models predicting the action of antiangiogenic drugs in tumor xenograft neglect tumor and host interactions[1,2]. Conversely, current tumor-in-host models[3,4],…
Read moreExposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development
Thursday 16 October, 2025
Objectives: Bintrafusp alfa* (M7824) is an innovative first-in-class bifunctional fusion protein composed of the two extracellular domains of transforming growth…
Read moreExploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis
Thursday 16 October, 2025
Objectives: To improve tamoxifen treatment, it is crucial to better understand the complex pharmacokinetics (PK) of tamoxifen and its major…
Read moreSemi-mechanistic PK model development of Sabestomig for Dose Selection
Thursday 16 October, 2025
Objectives: Bispecific antibodies, targeting two distinct antigens simultaneously, are an emerging biologic format. A good understanding of the pharmacokinetic (PK)…
Read more